You are here: Industry Insights > NASH

News List

NASH: Seizing Opportunities in the Untapped Market Neeta Ratanghayra
April 23, 2020
Nonalcholic steatohepatitis (NASH) is a hard to diagnose liver disease, characterized by steatosis, chronic inflammation, and progressive fibrosis that may lead to cirrhosis, liver failure. NASH is also a significant risk factor for the development of hep
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study) PharmaSources
January 12, 2023
HighTide Therapeutics Inc. announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH prnasia
January 04, 2022
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces the completion of the U.S. Phase I trial of ASC43F, an in-house developed...
Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH prnasia
December 03, 2021
Hepagene Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on innovative therapies for patients with liver diseases, today announced that it has screened the first patient...
Aramchol™ reduces fibrosis progression in 24 weeks EuropeanPharmaceuticalReview
November 02, 2021
Galmed Pharmaceuticals has announced results from the first 16 patients in the open-label part of the ARMOR Phase III study who underwent a scheduled post-baseline biopsy and were treated with Aramchol™ for fibrosis.
Gannex Announces U.S. IND Approval of ASC43F, a First-in-Class Dual-Target Fixed-Dose Combination for NASH prnasia
November 01, 2021
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA)...
Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases prnasia
October 14, 2021
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), announces today that the latest clinical and preclinical data of four NASH programs...
Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia prnasia
July 29, 2021
Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of ...
LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic prnasia
July 27, 2021
LISCure Biosciences, Inc. has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH).
Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist prnasia
June 17, 2021
Gannex announces positive topline results of safety and pharmacodynamic biomarkers from the U.S. Phase I trial of NASH drug farnesoid X receptor (FXR) agonist ASC42.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page